Evidence map›Paper›PMID 41344057›Full record

ArticleTranslational oncology2026

The PI3K pathway is a downstream effector of NRF2 activation in the esophagus.

Boopathi Subramaniyan, Yahui Li, Zhaohui Xiong, Chorlada Paiboonrungruang, Candice Bui-Linh, Francis Spitz, Xiaoxin Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Boopathi SubramaniyanSurgical Research Lab, Department of Surgery, Cooper University Health Care, Camden, NJ, 08103, USA.
Yahui LiSurgical Research Lab, Department of Surgery, Cooper University Health Care, Camden, NJ, 08103, USA.
Zhaohui XiongCoriell Institute for Medical Research, Camden, NJ, 08103, USA.
Chorlada PaiboonrungruangCoriell Institute for Medical Research, Camden, NJ, 08103, USA.
Candice Bui-LinhCoriell Institute for Medical Research, Camden, NJ, 08103, USA.
Francis SpitzSurgical Research Lab, Department of Surgery, Cooper University Health Care, Camden, NJ, 08103, USA; MD Anderson Cancer Center at Cooper, Camden, NJ, 08103, USA.
Xiaoxin ChenSurgical Research Lab, Department of Surgery, Cooper University Health Care, Camden, NJ, 08103, USA; Coriell Institute for Medical Research, Camden, NJ, 08103, USA; MD Anderson Cancer Center at Cooper, Camden, NJ, 08103, USA. Electronic address: chen-xiaoxin@cooperhealth.edu.

Funding

Mechanisms and Targeted Therapy of NRF2-high Esophageal Squamous Cell CarcinomaR01CA244236 · NCI · NORTH CAROLINA CENTRAL UNIVERSITY · PI CHEN, XIAOXIN LUKE, MAJOR, MICHAEL BENJAMIN · 2020 to 2025
$3.3M
NRF2-ACSS2 Axis in Alcohol-induced Metabolic Reprogramming and Esophageal PathologyR01AA030026 · NIAAA · CORIELL INSTITUTE FOR MEDICAL RESEARCH · PI XIAOXIN Luke CHEN, Guofang Zhang · 2022 to 2026
$2.9M
NCI NIH HHS R01 CA244236NIAAA NIH HHS R01 AA030026
6 · The paper itself

Abstract

Mutations in nuclear factor erythroid 2-related factor 2 (NFE2L2 or NRF2) occur in 10-22 % of esophageal squamous cell carcinoma (ESCC) cases and result in NRF2 activation, promoting tumor progression, and therapeutic resistance. Although previous studies suggested a link between NRF2 and kinases, specific kinases responsive to NRF2 activation remain to be fully identified. Using protein phosphorylation profiling and kinase activity profiling, we identified phosphatidylinositol 3-kinase (PI3K) pathway as a downstream effector in NRF2

Indexed as

Esophageal squamous cell carcinomaEsophagusNRF2PIK3CA

Identifiers

PMID41344057
PMCPMC12719973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.